Pharmacology
-
ORCA-3 replicates strong tobacco cessation results for cytisinicline
The ORCA-3 trial demonstrated that cytisinicline, a reformulated compound, significantly outperformed placebo by nearly six times in helping adults who smoke to quit.
-
Study shows earlier vasopressin initiation for sepsis reduced in-hospital mortality
Critical care expert Natalie Achamallah, MD, FCCP, said OVISS data support guidelines that recommend earlier vasopressin as well as lower norepinephrine doses.
-
UK trial finds propofol remains preferred ICU sedation agent
The recent A2B trial found that neither dexmedetomidine nor clonidine are superior to propofol and may increase risks of agitation and bradycardia.
-
As-needed albuterol-budesonide found to benefit mild asthma
Study author Craig LaForce, MD, and pulmonologist Kevin Fussell, MD, discuss findings from the BATURA trial and their clinical implications.
-
Ketamine vs etomidate for intubation in patients who are critically ill
Commonly used for sedation for endotracheal intubation, these drugs are often selected for their favorable hemodynamic profiles.
-
COURSE trial shows importance of biomarker testing in COPD
While overall the trial was negative, Meilan King Han, MD, MS, and Sanjay Ramakrishnan, MBBS, PhD, said it demonstrated the promise of tezepelumab for patients with baseline blood eosinophil counts ≥ 150 cells/µL.
-
Procalcitonin levels may guide antibiotic duration in patients with suspected sepsis
Paul Dark, MD, PhD, said a 10% reduction in duration of antibiotic use shown in a recent study may seem small, but in the context of antibiotic stewardship, a 10% reduction is important.
-
Admilparant phase 2 results raise hopes for combination treatment in pulmonary fibrosis
Fernando Martinez, MD, FCCP, said he expects the treatment options for fibrotic lung disease will soon become more complex—in a good way—as more effective therapies become available.
-
Dupilumab reverses airway inflammation, mucus hypersecretion in type 2 asthma
Lead author Mario Castro, MD, MPH, FCCP, said the VESTIGE trial is one of the first to show that we can reverse the disease process in asthma and substantially improve lung function.
-
Hope on the horizon for bronchiectasis
The combination of personalized therapies, novel and repurposed medications, and a multidisciplinary approach is transforming bronchiectasis from a condition that once had few treatment options into one that offers hope for improved management and even disease stabilization.
